Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials
1998

Goserelin in Early Breast Cancer Trials

Sample size: 4000 publication

Author Information

Author(s): M Kaufmann

Primary Institution: Department of Gynaecology and Obstetrics, Johann Wolfgang Goethe University, Frankfurt, Germany

Hypothesis

What is the safety and efficacy of goserelin compared to standard treatments in early breast cancer?

Conclusion

The ongoing trials will help define the role of goserelin in treating early breast cancer in premenopausal women.

Supporting Evidence

  • The trials will include data from over 4000 patients treated with goserelin.
  • Preliminary results are expected from the CRC trial in 1998 and from the ZEBRA and ECOG/SWOG trials in 1999.
  • The trials aim to compare disease-free survival rates and overall survival rates between goserelin and standard treatments.

Takeaway

Doctors are testing a medicine called goserelin to see if it helps women with early breast cancer better than the usual treatments.

Methodology

The trials involve comparing goserelin with standard treatments like chemotherapy and tamoxifen in various patient groups.

Limitations

The results are still pending and depend on the number of disease recurrences.

Participant Demographics

Premenopausal and perimenopausal women, primarily under 50 years of age.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication